FDA Issues Complete Response Letter for Nicotine Dependence Treatment

Achieve Life Sciences received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, a treatment for nicotine dependence. The letter cited manufacturing facility deficiencies and incomplete labeling, but no issues with the drug's clinical efficacy or safety. The company plans to resubmit the application in late 2026 with a new manufacturing partner.